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Current first-line treatments for major depressive disorder (MDD) include pharmacotherapy and
cognitive-behavioral therapy. However, one-third of depressed patients do not achieve remission after
multiple medication trials, and psychotherapy can be costly and time-consuming. Although non-
implantable neuromodulation (NIN) techniques such as transcranial magnetic stimulation, transcranial
direct current stimulation, electroconvulsive therapy, and magnetic seizure therapy are gaining
momentum for treating MDD, the efficacy of non-convulsive techniques is still modest, whereas use of
convulsive modalities is limited by their cognitive side effects. In this context, we propose that NIN
techniques could benefit from a precision-oriented approach. In this review, we discuss the challenges
and opportunities in implementing such a framework, focusing on enhancing NIN effects via a
combination of individualized cognitive interventions, using closed-loop approaches, identifying
multimodal biomarkers, using computer electric field modeling to guide targeting and quantify dosage,
and using machine learning algorithms to integrate data collected at multiple biological levels and
identify clinical responders. Though promising, this framework is currently limited, as previous studies
have employed small samples and did not sufficiently explore pathophysiological mechanisms
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associated with NIN response and side effects. Moreover, cost-effectiveness analyses have not been
performed. Nevertheless, further advancements in clinical trials of NIN could shift the field toward a
more ‘‘precision-oriented’’ practice.
Keywords: Major depressive disorder; transcranial magnetic stimulation; transcranial direct current
stimulation; electroconvulsive therapy; precision medicine
Introduction
Current psychiatric guidelines recommend several antide-
pressants and cognitive-behavioral psychotherapy (CBT) as
first-line treatments for major depressive disorder (MDD).1,2
However, more than one-third of depressed patients will
not achieve remission even after four adequate medical
prescriptions of antidepressant drugs.3 Moreover, des-
pite advances in psychopharmacology, even new medica-
tions can still produce several adverse effects that
reduce tolerability and increase risk.4 Psychotherapy,
in turn, is costly, time-consuming, does not suit all
patients, and is not readily available in remote areas of
the world.5
One possible explanation for the limited efficacy of
mainstream antidepressant treatments is that they are
typically applied in a ‘‘one-size-fits-all’’ and trial-and-error
paradigm, with little biological guidance – i.e., information
is mostly observational, with almost complete disregard
for the specific neurobiological mechanisms underpinning
the corresponding depressive symptomatology. To add-
ress this significant limitation in personalizing antidepres-
sant treatments, a new field of ‘‘precision psychiatry’’ has
been proposed, which aims to tailor medical treatment to
the characteristics of each patient.6
Although this concept is not necessarily new (e.g.,
blood transfusion is ‘‘guided’’ by blood type examination),
three new emerging tools6-8 are involved in the precision
psychiatry framework: 1) incorporating the biological path-
ways of disease – in psychiatry, this is represented by the
National Institute of Mental Health (NIMH) Research
Domain Criteria (RDoc), a framework that evaluates
mental illness at multiple clinical, endophenotypic, and
neurobiological levels9; 2) multimodal big data collection,
i.e., acquisition of clinical and biological data at scale, as
exemplified by the opportunities presented by interna-
tional consortiums such as the Enhancing NeuroImaging
Genetics through Meta-Analysis (ENIGMA)10 and mega-
cohorts such as the UK Biobank11; and 3) artificial intel-
ligence for analysis of multidimensional and complex
patterns in manifold data collected at multiple biological
levels.12,13 Although precision psychiatry is still in its
infancy, the continuous, rapid development of these tools
will reshape clinical and research practice, enhancing
treatment and minimizing adverse effects.6
Non-implantable neuromodulation (NIN) interventions,
such as transcranial magnetic stimulation (TMS), tran-
scranial direct current stimulation (tDCS), electroconvul-
sive therapy (ECT), and magnetic seizure therapy (MST),
are non-pharmacological, non-psychotherapeutic inter-
ventions with distinct efficacy, safety, tolerability, and
availability profiles.14-16 These techniques have been
developed over multiple decades to bridge the efficacy
and safety gaps of traditional antidepressant treatments,
with concrete results.17
Nevertheless, major caveats remain, such as limited
efficacy and significant adverse effects. In this context,
the development of a ‘‘precision NIN’’ approach could
both enhance clinical usability of NIN techniques (by
improving efficacy and/or maximizing tolerability) and
unveil their neurobiological mechanisms of action, which
to date remain poorly understood. Additional challenges
for precision NIN are the ability to combine them with
other interventions18 and their spatiotemporal resolution,
as the effects of NIN can be enhanced or decreased
according to the site of application of the coils or elect-
rodes and their synchronization with ongoing neuronal
activity.19 Knowledge acquired from computer modeling
and functional neuroimaging can be directed toward this
purpose (Figure 1).
In this review, we present the concept of precision NIN
as applied to antidepressant treatment. This framework
would also be useful for other neuropsychiatric disorders.
We first provide an overview of the state of the art and of
the main NIN antidepressant modalities, and then present
challenges and recent developments and opportunities of
using NIN in the framework of precision psychiatry.
Methods
We convened a group of national and global leaders on
the topics addressed in this review, such as MDD, neuro-
imaging, noninvasive brain stimulation, machine learn-
ing, neuropsychology, and precision psychiatry. These
authors were invited to address specific parts of the
manuscript, as well as to review its content as a whole.
The PubMed, Google Scholar, and Web of Knowledge
databases were searched from inception up to August
2019. Preference was given to recent comprehensive
reviews, meta-analyses, pivotal randomized clinical trials
that concerned NIN in the treatment of MDD, and highly
cited articles in the field, with a view to offering an up-to-
date and comprehensive perspective from experts. We
focused our review on clinical articles that investigated
MDD.
Non-implantable neuromodulation
Introduction and mechanisms of action
NIN techniques use electrical or magnetic energy targeted
at the brain20 (Figure 2). They do not require surgery, are
less invasive, and involve less risk than implantable tech-
niques, such as deep brain stimulation and vagus nerve
stimulation.22 They can be categorized into subconvulsive
and convulsive modalities, the former also often described
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as ‘‘non-invasive brain stimulation’’ (NIBS), which include
TMS and tDCS,15 while the convulsive modalities include
ECT and MST.23 Compared to the convulsive modalities,
NIBS does not require sedation or anesthesia, and pre-
sents excellent safety and tolerability profiles.24-28
The neurobiological rationale supporting NIBS in
depression is based on specific alterations of neurocir-
cuitry function, which can be normalized by targeted
stimulation of areas such as the dorsolateral prefrontal
cortex (DLPFC) – the cortical area most commonly
targeted, from early pilot studies to more recent, pivotal
NIBS trials.29-33 Besides the practical convenience of
safely targeting this area, the DLPFC is a key hub of the
frontoparietal network (FPN), which has been implicated
in the regulation of several processes, including decision-
making, working memory, and attention, and is impaired
in depression,34 particularly the left DLPFC.35 Hypoactiv-
ity of the FPN is associated with hyperactivity of the
default mode network (DMN), which may promote dep-
ressive behaviors and cognitions such as negative bias,
self-referential processing, and depressive rumination.36
The DLPFC is also a key node of the salience network
(SN), which plays a key role in cognitive control (i.e., the
self-regulation of thought, emotion, and behavior).37
Deficiencies in cognitive control and SN function and
structure appear not only in depression, but transdiag-
nostically across a variety of Axis I disorders,38 suggest-
ing that the mechanism of action of DLPFC-NIBS may be
pertinent not only to depression, but to other forms of
mental illness in which cognitive control is impaired.
NIBS to the DLPFC is thought to modulate the activity
of this brain area, thus promoting an increase in FPN
activity and a concomitant downregulation of DMN acti-
vity, leading to the improvement of depressive symp-
toms.39 Notably, anodal tDCS and high-frequency rTMS
usually increase cortical excitability, although the net
effect is also influenced by the underlying cortical acti-
vity.15 This rationale has been supported to some extent
by neuroimaging studies in depressed patients receiving
rTMS21,40 and by recent validation studies.41
In turn, ECT and MST – both of which are performed
in a controlled environment, under general anesthesia –
induce seizures via depolarization of neuronal net-
works.42 The mechanisms underlying the striking anti-
depressant effects associated with convulsive therapies
remain poorly elucidated,43 and may include increased
brain-derived neurotrophic factor (BDNF) levels,44 hippo-
campus and amygdala volumes,45,46 and hippocam-
pal functional connectivity.47 Nonetheless, it is unclear
whether the increase in hippocampal volume, a well-
documented effect,48 is an epiphenomenon or a neces-
sary mechanism underpinning therapeutic ECT effects,
as depression improvement is unrelated49 or even nega-
tively associated48 with this outcome. The inflammatory
theory associated with the convulsive NIN modalities is
promising, as inflammatory cytokines decrease after ECT
in depressed patients.50,51 As inflammation triggers the
kynurenine pathway, leading to oxidative stress and
serotonin depletion,52 rapid reduction of inflammation
could mitigate depressive symptoms.53
Figure 1 Precision non-implantable neuromodulation (NIN). In a precision NIN framework, advancements in related areas of
research and knowledge directly influence treatment protocols (parameters such as stimulation site, timing, and dose, as well
as combined behavioral/pharmacological interventions), aiming to increase individual antidepressant response.
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Transcranial magnetic stimulation
TMS is based on the principle of electromagnetic induction
via an electric alternating current passing through a coil.
The magnetic field, which varies over time (1.0-2.5 Tesla),
induces a secondary electric field, eliciting action potentials
when targeting the underlying cortex.54 The original
magnetic field passes through several layers (scalp, bone,
meninges, etc.), with no resistance and deflection, inducing
a relatively focal field.54
TMS can be delivered in various modalities – namely,
high-frequency (HF, 5-20 Hz), low-frequency (LF,p 1 Hz),
theta-burst (TBS), and deep TMS (dTMS).21,55 Since the
seminal study by Pascual-Leone et al.32 which showed
efficacy of HF-rTMS over the left DLPFC, many trials
have been performed. Of note, O’Reardon et al. rando-
mized 301 patients with MDD without concomitant
antidepressant use to receive either sham or active HF-
rTMS over the left DLPFC, and showed superior improve-
ment in depression in the active group.30,56 This study
provided pivotal data for FDA clearance of rTMS as
antidepressant therapy. The effectiveness of HF-rTMS
was further confirmed in two subsequent meta-analyses,
with positive results both in accelerating clinical response
to antidepressants57 and as monotherapy in unipolar
and bipolar depression.58 Low-frequency rTMS (LF-rTMS)
over the right DLPFC has demonstrated effectiveness in
the treatment of MDD,59 with both HF and LF being
regarded as first-line protocols.21 LF-rTMS can be espe-
cially advantageous when there is a high risk of seizures,
poor tolerability to pain, or when the patient does not
respond to HF-rTMS.55 Intermittent TBS, on the other
hand, provides a new avenue for busy clinical services
through exploration of more time-efficient rTMS protocols.
A recent multicenter non-inferiority randomized clinical trial
showed that intermittent theta-burst stimulation (iTBS),
which lasts only 3 minutes, was non-inferior to 37.5 minutes
of treatment with HF-rTMS. Both protocols were applied
over the left DLPFC.29 Finally, deep rTMS with an H-
shaped coil has also demonstrated clinical effectiveness in
MDD; this type of coil allows for deeper penetration of the
magnetic field into the brain.55
Network meta-analyses have further demonstrated
active rTMS to be superior to sham, albeit inferior to
ECT.17,60 In these studies, it was found that priming, HF-
rTMS, LF-rTMS, bilateral rTMS, and TBS were more
effective than placebo, although no active intervention
was superior to any other.
Based on these results, rTMS is considered a first-line
treatment for patients who have failed at least one trial
with an antidepressant medication.21,61 On the other
hand, the level of treatment resistance is known to be an
important negative predictor of response to rTMS.62 Less
is known regarding rTMS efficacy as a maintenance
Figure 2 Examples of NIN techniques (top panel) and the corresponding electric field distribution in the brain (bottom panel):
A) tDCS using 5  5 cm electrodes placed over the bilateral DLPFC; electrodes are colored red and blue to distinguish anode
(red) vs cathode (blue). B) TMS using the MagVenture B70 coil over the left DLPFC. C) Right unilateral ECT; conventional ECT
uses a bipolar waveform and therefore does not distinguish between anodal vs. cathodal electrodes. Electric field strengths are
normalized to their respective maximum value (Emax); absolute field strengths are very different across the modalities (o 1 V/m
for tDCS to4 100 V/m for TMS and ECT). Figure produced using SimNIBS software.21 DLPFC = dorsolateral prefrontal cortex;
ECT = electroconvulsive therapy; NIN = non-implantable neuromodulation; tDCS = transcranial direct current stimulation; TMS =
transcranial magnetic stimulation.
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treatment in depression. In patients who have responded
favorably to an acute course of rTMS, naturalistic studies
have found that relapse is more common without any
maintenance antidepressant strategy,63,64 while a meta-
analysis evaluating durability of HF-rTMS showed that the
antidepressant effects are small following a shorter acute
treatment.65 Current recommendations have not reached
a clear consensus regarding the most effective antide-
pressant maintenance protocol.21,61
Side effects of rTMS include the possible occurrence
of mild headache and pain at the site of stimulation,
although these symptoms typically resolve spontaneously
and the treatment is well tolerated overall.55 The most
serious side effect of rTMS is triggering of epileptic seiz-
ures, although this phenomenon is rare in clinical practice.
In fact, seizures have been found to be extremely rare,
and mainly occurred when rTMS protocols exceeded
safety guidelines.24 Animal studies suggest that even at
high intensities and prolonged exposure durations, there
is little likelihood of damage to brain structures.66,67
Finally, the only absolute contraindication to rTMS is the
presence of metallic and electronic material, such as
cochlear implants, in close contact with the coil.55
Transcranial direct current stimulation
For tDCS, an electric current of low intensity (usually 1.0-
2.5 mA) is applied to the brain, via two electrodes placed
over the scalp (anode and cathode), which is the most
common protocol.68 The current passes through the skin,
subcutaneous tissue, skull, and cerebrospinal fluid (CSF),
and into the gray and white matter. Due to the impedance
of the skull, only a fraction of the injected current reaches
the brain.69 In addition, as the conventional sponge-
electrode set is large (25 to 35 cm2) and the electrodes
are placed relatively far apart on the head, the induced
field is non-focal as the current flows from the anode to
the cathode.28 The injected electrical current does not
generate action potentials per se, but rather facilitates
or inhibits synaptic transmission, respectively, via an
increase or decrease in the frequency of action potentials
in endogenous neuronal firing.69 For depression, tDCS
montages employ anodal stimulation over the left DLPFC
(with contralateral, variable cathode sites), thus aiming to
counterbalance the hypoactivity of this brain area and
subsequent hyperactivity of the DMN.70
tDCS is considered a safe and well tolerated technique,
especially since the standard range of current intensities
used does not induce brain injury.25,26,28 The most com-
mon side effects include itching and tingling at the scalp
application sites.15 Skin burns are uncommon, and the
risk can be further reduced with proper soaking of the
electrodes, customized sponges, and adequate use of
saline solution.71
Due to its portability and ease of use, tDCS has been
investigated as an augmentative and substitute treat-
ment for antidepressant medications. In a factorial study
design, Brunoni et al.72 randomized 120 antidepressant-
free depressed patients to receive placebo, sertraline
only, tDCS only, or combined treatment with the two.72
The main study finding was that the combined treatment
led to a faster and greater response compared to the other
treatments. Subsequently, the same group31 designed a
non-inferiority, sham-controlled design to compare tDCS
vs. full-dose escitalopram. The study failed to show non-
inferiority of tDCS vs. escitalopram, although superiority
analyses revealed that tDCS was more effective than
placebo. Accordingly, recent meta-analyses have shown
that tDCS is superior to placebo for response, remission,
and depression improvement outcomes.73,74
Only three studies have investigated continuation of
tDCS sessions after the acute treatment phase.75-77 All
showed 6-month relapse rates varying from 25-50%.
Interestingly, the study that reported the lowest relapse
rate had tDCS performed twice a week,76 whereas the
one reporting higher relapse rates performed tDCS every
other week.75 Taken together, this suggests an intensive
tDCS treatment regimen is associated with lower relapse
rates, although these studies were limited by small
sample sizes and short follow-up periods.
While future randomized clinical trials involving tDCS in
the treatment of depression should continue to investigate
maintenance phase protocols, it would also be interesting
to individualize the delivered dose using computer models,
while evaluating the feasibility and safety of home-based
sessions.70,78 Furthermore, electrical stimulation with
different wave formats, such as transcranial alternating
current stimulation (tACS)79 or transcranial random noise
stimulation (tRNS),80 could be used to target MDD-related
oscillatory brain activity in the DLPFC, possibly in combina-
tion with individualized neurofeedback strategies.81
Convulsive modalities
ECT delivers a stimulus of alternating polarity pulses, with
an amplitude of 800-900 mA, via two electrodes placed
on the scalp.82 Although the procedure is considered a
second-line treatment for MDD due to the risk of cognitive
side effects, it is regarded as a first-line treatment in some
cases (e.g., MDD with acute suicidal or psychotic
features).21,83 ECT is more effective than sham, anti-
depressant medications and psychotherapy, and rTMS,84
achieving very high response and remission rates.21
Historically, bitemporal (or bifrontotemporal) electrode
positioning has been used, although right unilateral (RUL)
placement has gained currency as a modality with
relatively fewer cognitive side effects.82 In fact, there is
a complex relationship between ECT ‘‘dose’’ (total charge
delivered – a composite measure of current pulse ampli-
tude, pulse width, frequency, and number of pulses –
indexed by the seizure threshold, ST) and electrode
placement as a determinant of cognitive and antidepres-
sant outcomes, which can be partly explained by electric
field distribution.82 In the past, there was controversy as
to the comparative efficacy of RUL vs. bitemporal ECT,
the latter being considered more effective. However,
recent meta-analyses have found that high-dose RUL and
bitemporal ECT are equally effective,17,85 and considered
that previous RUL ECT trials that used lower doses
(e.g., less than six times the seizure threshold) might
have underestimated its treatment effects. More recently,
bifrontal ECT has been introduced as a form of ECT with
Braz J Psychiatry. 2020;00(00)
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efficacy comparable to that of bitemporal ECT, but fewer
side effects.86 Maintenance-phase ECT (weekly, biweekly,
or monthly sessions) is also considered effective and
tolerable, with increased efficacy in association with medi-
cations, especially the combinations of nortriptyline and
lithium87 and venlafaxine and lithium.88
Despite its effectiveness, ECT is limited due to the need
for infrastructure (general anesthesia, trained personnel,
and clinical evaluation),83 social stigma,89 and potential
cognitive side effects, including postictal disorientation,
anterograde amnesia, retrograde amnesia, and impair-
ments in multiple other cognitive domains, including verbal
fluency and executive function.21
The persistence, severity, and characterization of cog-
nitive impairment remain topics of great debate in the
current ECT literature, even after decades of research.90
Nevertheless, most acute ECT-related adverse events –
whether cognitive or non-cognitive – are mild, transient,
and self-limited; more severe cardiovascular and neuro-
logical complications are rare, and can be managed
through prophylactic and therapeutic measures.91
MST is a TMS variant that passes through the skull
unimpeded and results in a more focused superficial
electric field, concentrated in the cerebral cortex; hence,
there is minimal stimulation of inner brain structures, such
as the hippocampus.92 It delivers 25-100 Hz pulses for up
to 10 seconds to trigger generalized seizures.23 Poten-
tially, the more focal and limited electric field induced by
MST could be associated with a lower incidence of
cognitive side effects compared to ECT.93 Nevertheless,
MST seizures show less robust ictal expression, postictal
suppression, and generalization to the hippocampus
compared to ECT.94 To date, studies that have compared
MST and ECT found promising results, with MST having
antidepressant effects comparable to those of RUL ECT
and no cognitive side effects.23,95,96
Challenges and opportunities for precision
non-implantable neuromodulation
NIBS methods are not yet mainstream treatments for
depression. On the one hand, these techniques excel in
safety and tolerability; on the other, they have modest
antidepressant effects, are associated with variable costs,
and not widely available.15,17,97 ECT, although highly
effective, is limited by cognitive side effects and social
stigma, while MST is currently experimental. To promote
NIN applicability, we discuss the challenges and oppor-
tunities for increasing NIBS clinical effectiveness and
decreasing ECT- and MST-related side effects, in a
precision-oriented framework and in light of different
forms of ‘‘target engagement’’ (a target being either a
mechanism related to the disease or to the mode of action
of the intervention itself).98
The ‘‘how’’: combining non-invasive brain stimulation with
cognitive interventions
Evidence has demonstrated progressively that the neu-
robiological, behavioral, and antidepressant effects of
NIBS are dependent on the ‘‘state’’ of the targeted neural
area at the time of stimulation.18
For example, in depression, patients exhibiting higher
rostral anterior cingulate cortex (ACC) activity prior to
stimulation showed a better antidepressant response to
subsequent rTMS.99 This raises the prospect of experi-
mentally controlled ‘‘pre-shaping’’ of brain states, induced
by cognitive tasks and/or NIBS techniques, to more
effectively target stimulation to redress neurobiological
imbalances in depression. For instance, hyperconnectiv-
ity between the ACC and the medial prefrontal cortex
(mPFC) has been linked to maladaptive depressive
ruminations, and both CBT and rTMS, each alone, have
been shown to downregulate this dysfunctional brain
activity.18 Could pairing these interventions yield syner-
gistic effects? In an interesting pilot study, concurrent
rTMS and self-system therapy (SST, a modality similar to
CBT) were performed in (albeit only five) depressed
subjects, with positive results.100 Functional MRI was
used to assess brain change in the left DLPFC (which
was previously shown to be activated by SST-like tasks),
and rTMS was then targeted at this individual area while
an actual SST session was delivered.100 In a naturalistic,
open-label, multicenter study, 196 depressed patients
(most of whom were treatment-resistant) were assigned
to receive CBT sessions with simultaneous HF (10 Hz) or
LF (1 Hz) rTMS. Response rates reached 66%, with no
difference between rTMS modalities.101
Regarding tDCS, a study in a rodent slice model showed
that excitatory direct-current stimulation can strengthen
cellular mechanisms thought to underlie learning and
memory formation (long-term potentiation, LTP102). Criti-
cally, this enhancement occurred only when stimulation
was applied ‘‘online,’’ i.e., during LTP – there was no effect
when the identical stimulation was applied ‘‘offline,’’ i.e.,
prior to LTP. Behaviorally, parallel findings in rodents and
humans showed that excitatory tDCS during learning
enhanced memory for what was learned.103 Such enhance-
ment has been shown to depend critically on stimulation
during learning – the same stimulation applied prior to
learning can have null or even antagonistic effects.104 Such
basic neuroscience work suggests that the clinical efficacy
of tDCS could potentially be enhanced if it is applied during
learning that is designed to promote positive mood change,
e.g., CBT (so-called functional targeting).105
The combination of tDCS with psychotherapy is
particularly appealing. As both interventions target the
prefrontal cortex, their combination might result in a
positive synergy, with tDCS potentially enhancing a range
of cognitive processes recruited during psychotherapy.106
Various forms of psychotherapy have been combined with
tDCS. In an early, open-label study, Martin et al. combined
tDCS with a task designed to improve identification of
emotional states, in treatment-resistant depressed partici-
pants, with positive results (41% of study completers
displayed treatment response).107 In another recent pilot
study,108 patients with treatment-resistant depression (TRD)
received active tDCS (20 min, 2 mA, applied to the left
DLPFC) on 8 consecutive days and were randomly
assigned to receive either 2 hours of mindfulness-based
cognitive therapy (MBCT) or a 30-minute relaxation
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session immediately after each tDCS session. Results indi-
cate a longer lasting reduction of depressive symptoms and
enhanced cognitive processes in patients receiving the
tDCS/MBCT combination. An ongoing, multicenter study is
evaluating the efficacy of tDCS combined with group CBT.109
In this study, 192 depressed patients are being randomized
to 12 sessions of either: 1) CBT + active tDCS (2 mA,
30 minutes); 2) CBT+sham tDCS; or 3) CBT alone.109
The combination of tDCS with DLPFC activation tech-
niques, such as working memory training or combined
cognitive training, has also shown promising results in
healthy subjects,110 schizophrenia,111 mild cognitive
impairment,112 and cognitive impairment in Parkinson’s
disease.113 For combined treatment, tDCS has advan-
tages over rTMS: it does not produce noise, which can be
a distracting factor in rTMS sessions, and is portable.
Cognitive remediation, such as the training of specific
cognitive control processes, can also be performed
following an intervention with TMS or iTBS in a sequential
fashion, where cognitive remediation would be timed to
take advantage of the enhanced cognitive capacities
provided by the NIBS intervention. In this direction, an
ongoing trial (PACt-MD) is comparing the efficacy of tDCS
combined with cognitive remediation vs. double placebo
in slowing cognitive decline and preventing Alzheimer’s
disease in older persons with mild cognitive impairment,
or MDD with or without mild cognitive impairment (PACt-
MD, ClinicalTrials.gov, number NCT02386670).
Furthermore, given that other forms of psychotherapy,
such as interpersonal therapy, have been found to be
effective in the treatment of MDD,114 it would also be
interesting to study the combination of these techniques
with NIN.
The ‘‘when’’: combining NIBS with real-time neuroimaging
and electrophysiology
The neurobiological effects of NIBS can also be assessed
during or after application sessions,115-117 in what have
been termed ‘‘online’’ and ‘‘offline’’ approaches, respec-
tively.115
The ‘‘online’’ approach allows use of imaging techni-
ques to quantify local neural network properties and appli-
cation of NIBS so as to interfere with ongoing neuronal
processing, visualizing how NIBS modulates the level or
timing of neuronal activity with imaging and electrophy-
siology.115 For instance, a few studies have used fMRI to
evaluate the online propagation of TMS-induced effects
targeted to the prefrontal cortex.118-120 Further studies are
required to explore this propagation as a potential
biomarker for rTMS efficacy in the treatment of depres-
sive patients.
In the ‘‘offline’’ approach, one can increase or decrease
the excitability of a brain region and measure the
consequences thereof (i.e., with tDCS).115 For instance,
a recent study of volunteers with high trait anxiety
showed, through fMRI observation, that a single session
of the typical tDCS protocol used in depression sup-
pressed hyperactive fear signaling in the amygdala and
increased activity in frontoparietal attentional top-down
control regions.121
By these approaches, different combinations of NIBS
modalities can be synchronized with neural oscillatory
network activities, through real-time EEG or fMRI read-
outs which are further analyzed, thus closing the loop
between stimulation and neurobiological response.116
The ‘‘where’’: positioning and dose quantification
Optimal coil/electrode positioning is important to decrease
within- and between-subject heterogeneity in the induced
electric field and enhance clinical efficacy. Methods for
standardizing coil/electrode positioning are commonly
used, such as scalp landmark or hotspot-based coil
placement for rTMS,122 or headgear that secures the
electrodes in the desired location.123 Studies have shown
that even small changes in coil/electrode positioning can
change the induced neurobiological effects and nega-
tively affect clinical outcomes.124,125 More sophisticated
targeting approaches use individual or group-level anato-
mical and/or functional imaging to define the stimulation
site, including the possible use of multiple electrodes
to stimulate wider brain networks in a multifocal app-
roach.126 Targeting based on fMRI guidance has been
shown to produce stronger online rTMS effects compared
to other targeting strategies.127 The use of neuronaviga-
tion systems can greatly improve the spatial precision
of TMS. Furthermore, robotic coil-holder systems can
provide millimeter accuracy and continuous tracking of
the TMS coil. One such robotic system recently received
FDA 510(k) clearance.
‘‘Dose’’ quantification is key to determine the dose-
response gradient and to titrate the intervention para-
meters accordingly. Nonetheless, determining dose is
challenging in NIN, as various stimulation parameters are
employed (e.g., current intensity, waveform, and duration
for electrical stimulation; number, frequency, pattern, and
intensity for magnetic stimulation; frequency and duration
of treatment course), which influence one another in
complex interactions.128 The net result (excitation, inhibi-
tion, or no effect) is influenced by other concomitant inter-
ventions (pharmacological agents, cognitive tasks, other
NIBS interventions, and psychological interventions),26,129
as well as by network activity (i.e., brain state). For
convulsive therapies, there might be a trade-off between
using higher doses to produce greater clinical benefits but
with additional side effects.85
More recently, computational models have been used
to quantify electric fields (EFs) in brain regions of interest
(ROIs). In fact, there are freely available software
packages that perform electric field simulations using
high-quality MRI images (templates or individualized) via
a series of steps: 1) automated tissue segmentation of
structural MRI; 2) meshing of the different tissue compart-
ments to form a 3D model of the head and brain; 3)
processing DTI data to extract white-matter anisotropic
conductivity values; 4) incorporating electrodes and the
TMS coil on the head model; 5) assigning appropriate
electrical properties for the tissues and electrode/coil;
6) solving for the electric field and current density, via
numerical methods such as finite element or boundary
element methods; and 7) exporting, visualizing, and/or
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transforming electric field distribution to standard space
for group analysis.130 The resulting EFs can be graphi-
cally assessed; the results of EFs per ROI can be printed
out and mapped into standard spaces, such as MNI and
FreeSurfer, for analysis of correlations between current
distribution, clinical outcomes, and structural and func-
tional neuroimaging findings. These computational mod-
els allow researchers to 1) understand the biophysics and
mechanism of action for NIN modalities; 2) benchmark
and compare different technologies; and 3) quantify
interindividual variation in the induced dose as it relates
to clinical outcome. Further work is needed to investigate
the effects of EFs on brain tissue, and whether models
can be used for treatment planning and optimization.
The ‘‘who’’: identifying responders
The predictors of NIN response are mostly unknown.
Although treatment resistance in MDD is a robust clinical
predictor of poor response for most antidepressant
strategies, including NIN interventions,131-133 this might
be related more to the depressive episode per se than to
the intervention. In addition, the absence of improvement
in response to rTMS early during treatment predicts
continued non-improvement with further rTMS treat-
ment,134 whereas acute improvement with ECT predicts
final remission.135
Other predictors have shown mixed results. For instance,
in tDCS, higher ‘‘dose’’ was associated with better outcomes
in one meta-analysis,131 but a further sham-controlled trial
using a higher dose than previous ones yielded nonsigni-
ficant findings.136 Another study that applied tDCS over the
motor cortex also concluded that enhancement of tDCS
‘‘dose’’ does not necessarily increase the neurobiological
effects of stimulation, but might shift the direction of exci-
tability alterations.137 Furthermore, tDCS responders have
been found to display greater improvements in the MADRS
dysphoria and retardation factors compared to nonrespon-
ders.138 For rTMS, although most research to date has
focused more on testing the efficacy of different interven-
tions rather than on identifying subgroups of patients who
would respond better to a particular intervention,139 some
recent work suggests that the treatment may be most
effective for certain particular ‘‘biotypes’’ of depression,
detectable from whole-brain network connectivity on func-
tional MRI,140 and that the optimal rTMS parameters to
achieve antidepressant effect might vary depending on
treatment resistance, age, and sex.141 Moreover, greater
response to a LF-rTMS protocol has been associated with
lower MADRS retardation scores at baseline.142 Regarding
ECT, even first-line recommendations such as older age,
psychosis, and melancholic features21 were not consistently
identified in a meta-analysis.133 One study reported that
ECT responders displayed higher scores on a MADRS
dysphoria factor compared to nonresponders, while the
procedure had only a small effect on a MADRS vegetative
factor.143
Although relatively large trials have been conducted in
the NIN field,29,31,144 to the best of our knowledge, there is
no published research using machine-learning algorithms
to predict NIN response based on a clinical dataset – as
has already been done in pharmacological trials.145 For
example, using a gradient boosting model, Chekroud
et al.145 identified in STAR*D a dataset of 25 variables
that predicted depression response significantly above
chance. In another STAR*D analysis, Chekroud et al.146
identified which pharmacotherapies would be associated
with greater depression improvement for patients grouped
according to a cluster of depressive symptoms. These
approaches are important and fundamentally different
from statistical approaches to identification of predictors,
which are based on groups, not individuals.13,147 In fact,
statistical methods focus on inference – creating a
mathematical model that tests a hypothesis about how a
system behaves, whereas machine learning focuses on
prediction – i.e., finding generalizable predictive patterns
that aim to forecast future behaviors regardless of their
mechanistic basis12 (Figure 3). Additionally, through
employing almost no pre-assumptions and a nonlinear
function canvas, machine learning techniques can model
complex patterns that can identify relationships between
large amounts of data and data of diverse types,148,149
increasing the processing speed and output of predictive
models. For instance, a machine-learning modality known
as ‘‘deep learning’’ provides a promising approach for
analysis of the relationship between electromagnetic
fields and biological tissues (i.e., a head model is auto-
matically generated through MRI, with correspondence
between voxels to specific tissue types with given
electrical conductivity values).150
One concern about such approaches is the lack of
interpretability that the resulting models usually possess.
There is no clear way of interpreting complex nonlinear
models. In many clinical applications, including selection
of treatment or prediction of side effects, the clinician
does not need to fully comprehend how the machine is
processing information. In that case, the main concern is
how effectively the model can predict a specific outcome.
Preliminary work from our group (under review) used
data from the ELECT-TDCS31 to estimate single-subject
prediction of treatment response to tDCS, escitalopram,
or placebo. A total of 245 subjects were included, of
whom 55% were women (n=166) and 29% had TRD
(n=91).31 The feature dataset included baseline clinical,
sociodemographic, somatic, treatment-related, and
depression-related variables, as well as mood and anxiety
scales. Using a XGBoost tree boosting algorithm, we
could predict response to placebo, escitalopram and
tDCS with 45% (95%CI 39-52), 56% (50-61%), and 67%
(62-71%) balanced accuracy, respectively. This prelimin-
ary work reveals that ML-based approaches can predict
NIBS response above chance, facilitating further investi-
gation of this approach in upcoming studies using clinical
and biological data.
The identification of responders could potentially be
greatly enhanced by using biomarkers.151 For precision
NIN, biomarkers of treatment response would be espe-
cially useful, not only due to their predictive value but also –
particularly – to shed light on the mechanisms of action of
NIN. Importantly, biomarkers of disease might not be
necessarily related to treatment response, and a biomar-
ker for a pharmacological treatment might not necessarily
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apply to NIN. Among several potential biomarkers, we
propose that cognitive, neuroimaging, and neurophysio-
logical markers would be particularly useful for precision
NIN, since they are directly targeted by these techniques.
Structural and functional neuroimaging biomarkers
have indicated that the volume and thickness of certain
structures (e.g., portions of the prefrontal cortex and
anterior cingulate cortex), the resting-state connectivity of
certain networks, and the connectivity between ROIs
predict and are modified by the antidepressant effects of
NIBS.152-155 For instance, a recent study showed that
patients respond bimodally to rTMS: at the beginning of
treatment, nonresponders exhibited higher anhedonia
and lower connectivity in a brain network classically
associated with reward, consisting of the ventral teg-
mental area, striatum, and part of the VMPFC. This study
indicated that a subtype of depressive patients, identified
on the basis of syndromic and neuroimaging character-
istics, may respond better to rTMS.156 Also looking at
treatment-response biomarkers, researchers found early
response to rTMS treatment to be predictable by the
integrity of an extended salience-executive system,
indexed by fronto-insular connectivity and SN connectivity
with visual processing regions, although this was not true
for sustained response at 3-month follow-up.157 In an
exploratory analysis, researchers found that higher
functional connectivity between the DLPFC and striatum
predicted better treatment response to TMS in a group
of depressed patients.158 In another study140 that used
functional magnetic resonance imaging (fMRI) in a large,
multisite sample of 1,188 depressive patients, four distinct
neurophysiological subtypes (‘‘biotypes’’) were identified
on the basis of distinct patterns of dysfunctional con-
nectivity in frontostriatal and limbic networks. Patients in
‘‘biotype 1’’ were approximately three times more likely
to benefit from rTMS over the DMPFC than those in
‘‘biotypes’’ 2 or 4,140 although these findings need to
be interpreted with caution, given questions about their
replicability.159 For tDCS, a recent study showed that
larger gray-matter volumes in the left DLPFC at baseline
were further associated with antidepressant response to
tDCS, but not to escitalopram or placebo.160 Although the
effect sizes were small and had no individual-level
predictive value, these findings contribute to our under-
standing of the antidepressant effects of tDCS by showing
a specific association between the stimulated area and
further antidepressant response. So far, there does
not seem to be a consistent unique pattern of functional
or structural abnormality to predict the effect of non-
invasive neuromodulatory MDD interventions. In future,
combined use of biomarkers may help guide treatment
selection.161
Figure 3 Example of a machine learning pipeline. Analysis pipeline. A) Treatment outcomes of group are predicted according
to the feature dataset. B) Models are trained to classify responders and non-responders at the study endpoint. Performance is
evaluated in a repeated nested cross-validation paradigm. C) Features with the highest contribution to the model can be
identified. RCT = randomized clinical trial.
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Cognitive functions are another set of biomarkers worth
exploring in NIN trials. In depression, these are often
impaired independently of mood162-164 and are asso-
ciated with network dysfunctions.165,166 With the excep-
tion of ECT, NIBS appears to be cognitively safe in
healthy adults,25,167 with most single-session studies
indicating no cognitive decline, although exceptions have
been noted.168,169 In depressed patients, recent meta-
analyses found that NIBS techniques are not associated
with cognitive side effects.170,171 In contrast, cognitive
adverse effects are common in convulsive therapies.91
NIBS interventions could be designed to not only improve
mood, but to concomitantly induce cognitive enhance-
ment. The implementation of such a combined approach
would depend upon multiple factors, including NIBS
protocols, specific neurocircuitry and physiological pre-
mises, online and offline stimulation, pre-existing cogni-
tive difficulties, and other clinical and demographic
factors. For instance, NIBS administered over the PFC
induced improvement in a working memory task.172 Thus,
it can be supposed that, in MDD, PFC stimulation could
exert pro-cognitive effects, particularly in complex atten-
tion and working-memory domains.173 Nevertheless,
although some studies suggested cognitive improvement
in some tasks after rTMS in depressive patients, the
majority of studies showed no cognitive benefits after
NIBS.174 Possible reasons for null findings are limitations
of specific NIBS paradigms (e.g., poor spatial targeting,
inadequate dose), practice effects, reduced sensitivity
and specificity of the tests (e.g., paper-and-pen instead of
computerized tests), ceiling effects,174,175 and the lack of
concomitant cognitive activity. Cognitive functions could
also be leveraged to individualize treatment approaches
and predict treatment outcome. For example, baseline
cognitive performance or acute cognitive effects after the
first NIN session can predict antidepressant response to
NIN,176,177 and could therefore be used as a potentially
straightforward method for prediction in combination with
machine-learning approaches. Cognitive functions have
also been shown to be useful predictors for outcomes of
other treatment approaches, such as psychotherapy,178
and more long-term outcomes, such as return to work.179
Moreover, evaluating cognitive changes can provide
mechanistic insights into the antidepressant mechanisms
of action of NIN – e.g., by exploring whether they mode-
rate and/or mediate depression improvement – and into
NIN-induced changes in specific brain structures.180 In
this case, cognitive changes have been operationalized
as fundamental mechanisms of action, but also as more
translational processes, such as self-referential thoughts
and emotions (e.g., negative affect, rumination, regret,
cognitive bias). To date, most of this research is being
performed in healthy volunteers, but the transition to
clinical samples – also based on the idea of functional
targeting of similar functional and neuroanatomical
circuits using multimodal interventions – is slowly moving
forward.
Motor cortical excitability (MCE) measures were the
first neurophysiological biomarkers investigated in MDD,
as the motor cortex can be easily probed using single-
and paired-pulse TMS, which are associated with GABA
and glutamate activity in this structure.181,182 Studies
have shown that baseline measures of cortical inhibition
and facilitation were associated with antidepressant
response to tDCS, rTMS, and ECT,31,183,184 although
effect sizes were small. In addition, EEG-based neuro-
physiological parameters are associated with antidepres-
sant response to rTMS.185,186 More recently, it has been
advocated that prefrontal excitability indexed using TMS-
evoked potentials and TMS-EEG systems might be more
a specific marker of NIN effects compared to MCE, as
these methods can probe the cortical excitability of frontal
brain areas implicated in depressive pathophysiology,
with high temporal resolution.187 However, these techni-
ques are still novel and technically challenging, and it is
still unclear which indexes better represent GABA acti-
vity.116 These limitations notwithstanding, promising find-
ings have been observed using this biomarker modality to
predict NIN response.188-190
Other biological markers have also been explored in
NIN, including genetic and non-genetic peripheral bio-
markers and heart rate variability.44,191-199 Although some
positive findings were found, results have been incon-
sistent, and mostly derived from open studies. In addition,
the identification of candidate genes has been challenged
by more recent studies showing that most previous
findings are likely to be false positives.200 Likewise, the
literature on peripheral depression biomarkers is fraught
with bias.201,202
Limitations and perspectives
Although promising, the precision NIN framework should
be pursued and expanded with a view to improved clinical
applicability. For instance, despite the investigation of
several biomarkers, most positive findings have emerged
from poorly controlled exploratory studies using small
sample sizes, thus requiring further validation. In this
regard, properly controlled studies of biomarkers could
further expand our knowledge of their role in the
pathophysiological processes related to MDD and help
predict response to treatment. Strategies that would
enhance biomarker validity include adequately powered
sample sizes and a priori hypotheses for the role of the
markers of interest. Novel clinical trials investigating NIN
interventions should embed the investigation of biomar-
kers in their design. For certain NIN modalities in which
clinical efficacy is already proven, such as most variants
of rTMS and ECT, sham-controlled trials are not neces-
sary and, in fact, not feasible from an ethical perspective,
as equipoise to placebo cannot be assumed. Therefore,
academic centers that perform rTMS and ECT should
incorporate systematic data collection of clinical and
demographic characteristics – as well as questionnaires,
inventories and scales measuring depression and cogni-
tive changes during treatment – into their clinical routine.
Ideally, molecular and neuroimaging biomarkers should
be collected as well, and data could be shared by different
data centers. Such an approach is exemplified by the
Global ECT-MRI Research Collaboration, which already
includes more than 22 centers collecting ECT and MRI
data worldwide.48 On the other hand, for other NIN
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interventions, such as tDCS and MST, phase-3 controlled
studies are still necessary, as clinical efficacy remains
unproven. For such trials, we recommend that investiga-
tors incorporate a comprehensive set of biomarkers to
be investigated within the context of the primary study
hypothesis. In this context, the framework of ‘‘target enga-
gement’’ and ‘‘target validation’’ is useful – i.e., those
biomarkers deemed most promising on the basis of
preclinical and early clinical findings should be investi-
gated as predictors and moderators of clinical response.
Likewise, even though the logic of using approaches
such as machine-learning in individual patient data and
meta-analytic datasets is sound and necessary, any
findings would still be retrospective, requiring further
validation in novel datasets distinct from those on which
the classifiers were trained, to determine generalizability.
This necessitates a global effort in scientific collaboration
and data sharing, with particular focus on overcoming
difficulties in access to the literature and primary data held
beyond paywalls. In this sense, open-access initiatives
are welcome, as are promising changes in business
models of academic publishing. In this context, one of
the leading journals of the field (Brain Stimulation) has
become fully open-access as of January 1, 2020.203
Moreover, policies ensuring that properly anonymized
data from clinical trials (whether sponsored by public or
private institutions) can be shared under request should
be endorsed by regulatory agencies to further promote
data-sharing initiatives.
Machine learning-guided intervention trials in NIN are
still a necessary second step to further validate predictive
algorithms.204 Cost-effectiveness analyses should also
be performed to verify whether a precision-oriented app-
roach is economically advantageous: on the one hand,
enhancing efficacy and decreasing side effects can
increase individual benefits and reduce treatment cost;
on the other, the additional costs of using precision tech-
niques should be considered. For instance, the advan-
tages of tDCS include its low cost and portability, but the
neuroimaging scans and individualized electrode posi-
tioning required before treatment could make these
advantages moot if additional gains in efficacy and effici-
ency are not achieved. Although not discussed in the
present review, computational and preclinical studies
would be useful to deepen our understanding of NIN
techniques,205 while studies in healthy volunteers are
needed to narrow the parameter spaces of these
techniques (for instance, by using closed-loop bayesian,
adaptive optimization).206
Finally, it should be noted that the selection of studies
for this special article was unsystematic, i.e., publications
were deemed relevant and selected according to the
perspective of the authors, with the inherent subjective
limitations that such a narrative entails.
Conclusions
Depressive disorders are prevalent, disabling conditions.
Conventional antidepressant treatments fail to induce
remission in approximately one-third of patients with
MDD, may result in intolerable side effects (first-line
medications), or may be expensive and time-consuming
(psychotherapy). Moreover, such therapies are still pre-
scribed on a ‘‘trial-and-error’’ basis, in which achievement
of a satisfactory response can take several months.
In this context, NIN techniques are increasingly con-
sidered safe, tolerable, and effective, whether as mono-
therapy or augmented with other interventions, such as
medications and psychotherapy. Furthermore, as stimu-
lation parameters can be directed to specifically affected
brain areas, NIN is also undergoing a paradigm shift
towards a precision-oriented framework that takes into
consideration ‘‘knowledge about brain circuits that under-
lie complex cognitive, emotional and self-reflective func-
tions’’ in order to guide individualized patient-oriented treat-
ments.36 Ultimately, this new framework does not rely
solely on observable clinical outcome information, but also
on data from multiple biological levels, from cells to circuits.
As open-access initiatives across the globe give space to
merging and analyzing large datasets and subjects in
clinical trials are increasingly assessed via multimodal app-
roaches, a greater understanding of methods for handling
big data will be mandatory for specialists in the field.
In this context, future NIN-related research would
benefit from a focus on optimization of its parameters,
discovery of remission- and response-related biomarkers,
elucidation of cognitive safety and enhancement mechan-
isms, and advancement of scientific knowledge related to
mechanisms of NIN action.
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